- Trials with a EudraCT protocol (852)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (66)
852 result(s) found for: Rheumatoid Arthritis.
Displaying page 31 of 43.
EudraCT Number: 2014-003849-10 | Sponsor Protocol Number: CAIN457F2336 | Start Date*: 2015-03-17 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab (150 mg) in pre-filled syringe, with or without loading regimen, to demonstrate efficacy, saf... | |||||||||||||
Medical condition: Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) CZ (Completed) BE (Completed) BG (Completed) DE (Completed) GB (Completed) PL (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005026-30 | Sponsor Protocol Number: SB4-G31-RA | Start Date*: 2013-08-15 | |||||||||||
Sponsor Name:Samsung Bioepis Co., Ltd. | |||||||||||||
Full Title: A Randomised, Double-Blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB4 Compared to Enbrel® in Subjects with Moderate to ... | |||||||||||||
Medical condition: Subjects with Moderate to Severe Rheumatoid Arthritis despite Methotrexate Therapy. The intended use of SB4 is Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (P... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LT (Completed) CZ (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001579-40 | Sponsor Protocol Number: P04440 | Start Date*: 2007-04-02 | |||||||||||
Sponsor Name:Schering-Plough France | |||||||||||||
Full Title: Study of peripheral enthesitis with ultrasonography doppler in spondyloarthropathies treated with infliximab | |||||||||||||
Medical condition: Spondyloarthropathies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) ES (Completed) DK (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007510-30 | Sponsor Protocol Number: ARRAY 797-201 | Start Date*: 2009-02-09 | |||||||||||
Sponsor Name:Array BioPharma Inc. | |||||||||||||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF 12 WEEKS OF TREATMENT WITH ... | |||||||||||||
Medical condition: ANKYLOSING SPONDYLITIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005021-39 | Sponsor Protocol Number: CAIN457F2308 | Start Date*: 2016-08-04 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab in prefilled syringes, to compare efficacy at 16 weeks with placebo and to assess safety and ... | |||||||||||||
Medical condition: Ankylosing Spondyloarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010955-29 | Sponsor Protocol Number: 10031983 | Start Date*: 2009-07-13 |
Sponsor Name:Division of Clinically Immunology and Rheumatology, AMC | ||
Full Title: Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease. | ||
Medical condition: Pre-clinical RA patients with a high risk on developing the disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000241-74 | Sponsor Protocol Number: CNTO148AKS3001 | Start Date*: 2014-12-30 | |||||||||||
Sponsor Name:Janssen Biologics, BV | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects with Active Ankylosing Spondylitis | |||||||||||||
Medical condition: Ankylosing spondylitis (AS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005157-29 | Sponsor Protocol Number: PHRR-04/PG/SPAXIM | Start Date*: 2007-04-27 | ||||||||||||||||
Sponsor Name:CHRU-TOURS | ||||||||||||||||||
Full Title: EFFET DU METHOTREXATE SUR LA RELATION DOSE - EFFET DE L'INFLIXIMAB DANS LA SPONDYLARTHRITE ANKYLOSANTE | ||||||||||||||||||
Medical condition: Les patients seront traités par infliximab, avec ou sans méthotrexate associé, selon la pratique habituelle en accord avec le libellé de l’A.M.M. Seuls le nombre de prélèvements sanguins et de visi... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000844-56 | Sponsor Protocol Number: TOPAS2011 | Start Date*: 2011-07-12 | |||||||||||
Sponsor Name:Charité Universitätsmedizin Berlin | |||||||||||||
Full Title: UsTekinumab for the treatment Of Patients with active Ankylosing Spondylitis (TOPAS) – a 28-week, prospective, open-label, proof-of-concept study | |||||||||||||
Medical condition: Ankylosing spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000615-33 | Sponsor Protocol Number: CONSUL2016 | Start Date*: 2016-07-29 | |||||||||||||||||||||
Sponsor Name:Charite Universitaetsmedizin | |||||||||||||||||||||||
Full Title: Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural damage in the spine over two years in patients with ankylosing... | |||||||||||||||||||||||
Medical condition: ankylosing spondylitis (AS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-002631-33 | Sponsor Protocol Number: CAIN457A2209 | Start Date*: 2009-01-14 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: Randomized, placebo controlled, double blind, multi-center phase II proof-of-concept study to assess the efficacy of AIN457 in patients with moderate to severe ankylosing spondylitis | |||||||||||||
Medical condition: Ankylosing Spondylitis (AS), which belongs to seronegative spondyloarthropathies (SpA). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003065-95 | Sponsor Protocol Number: AS0011 | Start Date*: 2019-06-11 | |||||||||||
Sponsor Name:UCB Biopharma SRL | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS | |||||||||||||
Medical condition: Ankylosing spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) BG (Completed) FR (Completed) ES (Restarted) CZ (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002620-18 | Sponsor Protocol Number: IM101-046 | Start Date*: 2005-05-13 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Multi-National Randomized, Double-Blind, Exploratory Study of Abatacept versus Placebo in Preventing the Development of Rheumatoid Arthritis in Adult Subjects with Undifferentiated Inflammatory A... | ||
Medical condition: Rheumatoid Arthritis, NOS | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Completed) BE (Completed) IT (Completed) ES (Completed) | ||
Trial results: Removed from public view |
EudraCT Number: 2011-002325-22 | Sponsor Protocol Number: I1F-MC-RHAO | Start Date*: 2013-09-26 | |||||||||||
Sponsor Name:Eli Lilly & Company | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Patients with Active Ankylo... | |||||||||||||
Medical condition: Spondylitis, Ankylosing | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004981-20 | Sponsor Protocol Number: CNTO1959PSA3004 | Start Date*: 2021-08-10 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhi... | |||||||||||||
Medical condition: Psoriatic arthritis (PsA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) LV (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) SI (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) HR (Trial now transitioned) GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003232-21 | Sponsor Protocol Number: C0524T12 | Start Date*: 2006-12-11 |
Sponsor Name:Centocor B.V. | ||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Intravenously, in Subjects with Active Rheumatoid Arthri... | ||
Medical condition: Rheumatoid Arthritis (RA) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) HU (Completed) LV (Completed) LT (Completed) MT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-004131-84 | Sponsor Protocol Number: ChronIA001 | Start Date*: 2022-02-14 | ||||||||||||||||
Sponsor Name:Erasmus Medical Center | ||||||||||||||||||
Full Title: Chronotherapy in Inflammatory Arthritis (ChronIA trial): a randomized controlled trial comparing the effectiveness of morning and evening dosing of tofacitinib extended-release | ||||||||||||||||||
Medical condition: Rheumatoid arthritis or psoriatic arthritis according to respectively 2010 criteria or CASPAR criteria | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003405-94 | Sponsor Protocol Number: ABY-035-202 | Start Date*: 2020-05-05 | |||||||||||
Sponsor Name:ACELYRIN, Inc. | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial inpatients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics a... | |||||||||||||
Medical condition: Active Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) HU (Completed) CZ (Completed) DE (Completed) ES (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000563-96 | Sponsor Protocol Number: 0881A-101548 | Start Date*: 2004-11-12 |
Sponsor Name:Wyeth Pharmaceuticals | ||
Full Title: A 24-MONTH, RANDOMIZED, DOUBLE-BLIND, TWO PERIOD STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE COMBINATION OF ETANERCEPT AND METHOTREXATE AND METHOTREXATE ALONE IN SUBJECTS WITH ACTIVE EARLY RHE... | ||
Medical condition: Rheumatoid Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) SE (Completed) NO (Completed) FI (Completed) ES (Completed) AT (Completed) IE (Completed) IT (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003214-41 | Sponsor Protocol Number: CNTO1959PSA3003 | Start Date*: 2019-01-22 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthrit... | |||||||||||||
Medical condition: Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) GB (Completed) ES (Completed) PL (Completed) PT (Completed) HU (Completed) BG (Completed) GR (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
